News of Note—NIH Zika vaccine trial, VBI Vaccines and more


Here is some other vaccine news of note for the week:

> The National Institutes of Health started a first-in-human study of a NIAID-developed live attenuated Zika virus vaccine candidate. Release

> VBI Vaccines appointed Christopher McNulty as its chief financial officer and head of business development. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> The Securities and Exchange Commission decided against further action after an investigation into possible securities law violations at Sinovac. Release

> BiondVax has moved manufacturing for its universal flu vaccine candidate to a new facility in the Jerusalem Bio Park. Release

Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.